Description:

S0502 Adverse Event Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7FD7-A1A5-7312-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7FD7-A1A5-7312-E034-0003BA3F9857

Keywords:
Versions (4) ▾
  1. 9/19/12
  2. 1/8/15
  3. 1/9/15
  4. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Gastrointestinal Stromal Tumor NCT00324987 Toxicity - S0502 Adverse Event Form - 2320351v1.0

Intergroup Coalition Against Sarcomas (ICAS)

  1. StudyEvent: S0502 Adverse Event Form
    1. Intergroup Coalition Against Sarcomas (ICAS)
Header
Adverse Events
Were adverse events assessed during this time period?
CTC Adverse Event Term
CTC Adverse Event Attribution Code (* Attribution codes: 1-unrelated 2-unlikely 3-possible 4-probably 5-definite)
Adverse event status code (** Status codes since baseline or last cycle: 1-new 2-continues at same or lower grade 3-increased grade OR improved then worsened)
Comments

Similar models